Abstract: The present invention is directed to compounds of Formula I: that are potassium channel modulators and pharmaceutical compositions thereof. The present invention is further directed to methods of treatment using the compounds and pharmaceutical compositions of the invention. The present invention is still further directed to synthetic processes for producing the compounds of the invention.

Abstract: The present invention is directed to compounds of Formula I: that are potassium channel modulators and pharmaceutical compositions thereof. The present invention is further directed to methods of treatment using the compounds and pharmaceutical compositions of the invention. The present invention is still further directed to synthetic processes for producing the compounds of the invention.

Abstract: The present invention relates generally to a method for identifying molecules that bind the R7.1 epitope of LFA-1 or bind LFA-1 such that the R7.1 epitope is modified. The present invention further relates to a method for determining occupancy of the LFA-1 receptor by molecules that bind to the R7.1 epitope or bind LFA-1 such that the R7.1 epitope is modified after administration to a subject. The present invention further relates to molecules useful in the methods of the invention.

Abstract: The present invention relates generally to a method for identifying molecules that bind the R7.1 epitope of LFA-1 or bind LFA-1 such that the R7.1 epitope is modified. The present invention further relates to a method for determining occupancy of the LFA-1 receptor by molecules that bind to the R7.1 epitope or bind LFA-1 such that the R7.1 epitope is modified after administration to a subject. The present invention further relates to molecules useful in the methods of the invention.

Abstract: This invention relates to macrocyclic molecules which inhibit metalloproteinases, including aggrecanase, and the production of tumor necrosis factor (TNF). In particular, the compounds are inhibitors of metalloproteinases involved in tissue degradation and inhibitors of the release of tumor necrosis factor. The present invention also relates to pharmaceutical compositions comprising such compounds and to methods of using these compounds for the treatment of inflammatory diseases.

Abstract: This invention relates to carbocyclic and heterocyclic fused-ring quinolinecarboxylic acid compounds, to pharmaceutical compositions comprising such compounds, and to methods of using such compounds for the treatment and/or prevention of organ transplantation rejection, graft versus host disease, autoimmune diseases, chronic inflammatory diseases, including but not limited to psoriasis and rheumatoid arthritis, and cancer in a mammal.

Abstract: The present invention relates to vinylogous hydroxamic acids, processes for their manufacture, pharmaceutical preparations containing them, and their use in the treatment of various disorders.

Abstract: Lanosterols substituted in the 14 and/or 15 position(s) which are active in inhibiting lanosta-8,24-dien-3.beta.-ol 14.alpha.-methyl-demethylase activity, suppressing 3-hydroxy-3-methylglutaryl coenzyme A reductase (HMGR) activity, decreasing cholesterol synthesis and reducing serum cholesterol levels are disclosed.

Abstract: Lanosterols substituted in the 14 and/or 15 position(s) which are active in inhibiting lanosta-8,24-dien-3.beta.-ol 14.alpha.-methyl-demethylase activity, suppressing 3-hydroxy-3-methylglutaryl coenzyme A reductase (HMGR) activity, decreasing cholesterol synthesis and reducing serum cholesterol levels are disclosed.

Abstract: 1-Thioether-1-acylaminophosphatidylcholine compounds are structural analogs of platelet activating factor and useful for inhibition of phospholipase A.sub.2, reduction of blood pressure, and alleviation of inflammation.

Abstract: Stable biologically active thromboxane A.sub.2 analogues having the formula: ##STR1## wherein R.sup.1 is OR.sup.3, where R.sup.3 represents hydrogen or a pharmaceutically acceptable cation or lower alkyl group; orR.sup.1 is NR.sup.4 R.sup.5 where R.sup.4 and R.sup.5 are the same or different substituents selected from the group consisting of hydrogen and lower alkyl group; andR.sup.2 is hydrogen or an --OH group.The thromboxane analogues are potent thrombotic agents, useful in cardiovascular treatment.

Abstract: Stable biologically active thromboxane A.sub.2 analogues having the formula: ##STR1## wherein R.sup.1 is OR.sup.3, where R.sup.3 represents hydrogen or a pharmaceutically acceptable cation or lower alkyl group; orR.sup.1 is NR.sup.4 R.sup.5 where R.sup.4 and R.sup.5 are the same or different substituents selected from the group consisting of hydrogen and lower alkyl group; andR.sup.2 is hydrogen or an -OH group.The thromboxane analogues are potent thrombotic agents, useful in cardiovascular treatment.

Abstract: Stable biologically active thromboxane A.sub.2 analogues having the formula ##STR1## wherein R.sup.1 is OR.sup.3, where R.sup.3 represents hydrogen or a pharmaceutically acceptable cation or lower alkyl group; orR.sup.1 is NR.sup.4 R.sup.5 where R.sup.4 and R.sup.5 are the same or different substituents selected from the group consisting of hydrogen and lower alkyl group; andR.sup.2 is hydrogen or an --OH group.

Abstract: Stable biologically active 6,9 .alpha.-thiaprostacyclin derivatives having the formula ##STR1## wherein X represents >S, >SO or >SO.sub.2 ;Y represents (E) and(Z)-->C.dbd.CH--CH.sub.2 CH.sub.2 CH.sub.2 COOR,(E)-->CH--CH.dbd.CH--CH.sub.2 CH.sub.2 COOR or >CH--CH.sub.2 --CH.sub.2 --CH.sub.2 --CH.sub.2 COOR; andR represents hydrogen, a pharmaceutically acceptable cation or a pharmaceutically acceptable lower alkyl group.

Abstract: Stable biologically active thromboxane A.sub.2 analogues having the formula: ##STR1## wherein R.sup.1 is OR.sup.3, where R.sup.3 represents hydrogen or a pharmaceutically acceptable cation or lower alkyl group; orR.sup.1 is NR.sup.4 R.sup.5 where R.sup.4 and R.sup.5 are the same or different substituents selected from the group consisting of hydrogen and lower alkyl group; andR.sup.2 is hydrogen or an --OH group.The thromboxane analogues are potent thrombotic agents, useful in cardiovascular treatment.

Abstract: Unsaturated alcohols, thiols and thioesters are cyclized by a phenyl selenenyl halide; wherein the conformation flexibility of the unsaturated alcohol, thiol or thioester is selected such that the hydroxy group, thiol group or thioester group is capable of internal addition to at least one unsaturated bond in said alcohol, thiol or thioester; and wherein the ratio of the phenyl selenenyl halide to said unsaturated alcohol, thiol or thioester is 0.9-1.5 to 1. In a preferred embodiment, oxygen isomers and sulfur analogs of prostacyclin of the formula ##STR1## wherein X= ##STR2## Y=(E)- and (Z)- >C.dbd.CH--CH.sub.2 CH.sub.2 CH.sub.2 COOR; (E)- >CH--CH.dbd.CH--CH.sub.2 CH.sub.2 COOR; andR=any pharmaceutically acceptable cation or lower alkyl group comprising 1 to 4 carbon atoms are formed by:(1) cyclizing a PGF.sub.2.alpha. prostaglandin derivative or a 9.alpha. thio or 9.alpha. -thioester analog of prostaglandin PGF.sub.2.alpha.

Abstract: Stable biologically active aromatic prostacyclin analogues of the formula ##STR1## wherein X represents ##STR2## and R represents hydrogen, a pharmaceutically acceptable cation or a pharmaceutically acceptable lower alkyl group, are useful in the treatment of blood platelet aggregation and vascular constriction.